Drug Discovery World

FEBRUARY 13, 2023

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. DDW: Could you explain the process of transcriptomics? SB: Absolutely.

RNA 130

RNA Drugs Immune Response Therapies 130

Drug Discovery World

JANUARY 27, 2023

Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic. News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer.

RNA 130

RNA Therapies Drugs Virus 130

Drug Discovery World

DECEMBER 21, 2023

DDW’s top 10 most popular articles for 2023 reflect the key subjects in drug discovery and development. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. This well-read article featured in the DDW Winter 22/23 issue’s Cell & Gene Therapy Guide.

FDA Approval 148

FDA Approval Therapies Small Molecule Clinical Trials 148

Alta Sciences

APRIL 16, 2024

Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs pmjackson Tue, 04/16/2024 - 19:04 The gene therapy landscape continues to accelerate in preclinical and clinical research, with programs constantly in development for targeted, personalized medicines. But how are PCR analysis techniques applied?

Therapies 52

Therapies DNA RNA Laboratories 52

Drug Discovery World

APRIL 24, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. The post Free webinar today: How is NGS informing oncology drug discovery? Register now.

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

APRIL 18, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. The post Register now to learn how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW).

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

APRIL 11, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. The post Webinar: Find out how NGS is informing oncology drug discovery appeared first on Drug Discovery World (DDW).

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

APRIL 4, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. The post Next-generation sequencing and oncology drug discovery appeared first on Drug Discovery World (DDW).

RNA 130

RNA Medical Schools Drugs Clinical Trials 130

Drug Discovery World

APRIL 3, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130

RNA Medical Schools Clinical Trials Drugs 130

Drug Discovery World

SEPTEMBER 21, 2023

Professor De Strooper said: “Our study sheds light on the previously murky waters of AD, revealing a potential key player in neuronal loss – an RNA gene called MEG3, and the process of necroptosis.

Disease 263

Disease RNA Research Science 263

Drug Discovery World

JULY 15, 2024

Dr Alexandra Sapetschnig, Group Leader at STORM Therapeutics, described the event as one that “really set the agenda for oncology research in 2024” through the display of new approaches and methods that are expanding opportunities in drug development. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Drug Discovery World

MAY 23, 2024

Reece Armstrong speaks to Samuel Deutsch , Chief Scientific Officer of Nutcracker Therapeutics about the RNA landscape and how it can benefit the development of immunotherapies. RA: What role does RNA play in the development of effective immunotherapies? SD: This is definitely a challenge.

RNA 148

RNA Therapies Engineering Disease 148

Drug Discovery World

SEPTEMBER 15, 2023

Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development.

Pharma Companies 130

Pharma Companies Drugs RNA Vaccine 130

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.

RNA 246

RNA Engineering Therapies Disease 246

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding. Northern Ireland “Northern Ireland is a medtech super-hub,” says Saleko.

Drugs 190

Drugs Science Therapies Targeted Protein Degradation 190

Drug Discovery World

MARCH 6, 2023

Supporting innovative science Bobby Soni, Chief Business Officer at BioInnovation Institute, said: “BII’s mission is to create products for the welfare of people and society, and we believe that BII’s support of the innovative science in this Venture Lab cohort will deliver on that promise.”

Science 130

Science RNA Disease International 130

Drug Discovery World

SEPTEMBER 27, 2023

Epigenetics, often referred to as the ‘software’ of gene regulation, encompasses chemical modifications to DNA, such as methylation, and modifications of other proteins that organise DNA in the nucleus, known as histones, as well as RNA.

DNA 290

DNA Regulations Disease RNA 290

Drug Discovery World

AUGUST 1, 2024

They are called: Optimising AAV capsid purification through improved analytics How transcriptomics is driving drug discovery Scandinavia: Insight into opportunities for drug discovery In the first article, Svea Cheeseman from Refeyn explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies.

Drugs 130

Drugs Therapies Marketing Production 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

APRIL 11, 2023

The molecule, known as lissodendoric acid A, appears to counteract other molecules that can damage DNA, RNA and proteins and even destroy whole cells. Dysregulation of mitophagy is closely linked to the development of several diseases, with USP30 modulation offering a potential treatment.

Drug Research 130

Drug Research Research Drugs RNA 130

Drug Discovery World

APRIL 30, 2024

Reece Armstrong explores the potential and future opportunities for mRNA-based therapies. Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43

Therapies 130

Therapies RNA Vaccine Small Molecule 130

DrugBank

JULY 24, 2024

For example, PROTACs targeting STAT3, a protein crucial for tumor growth, have shown promise where conventional therapies have failed. Similarly, PROTACs can target and degrade overexpressed proteins, offering a way to overcome drug resistance, a common issue in cancer treatment.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

MARCH 13, 2024

In terms of drug discovery, every year the agency awards national grants through the Singapore Therapeutics Development Review (STDR), designed to boost the quality and quantity of drug development and biotech pipelines in Singapore 3.

Government 174

Government Science Pharmaceuticals Vaccine 174

DrugBank

MAY 15, 2024

Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Target Review

MAY 27, 2024

Caris Discovery, the therapeutic research arm of Caris Life Sciences, was launched to address the paucity of novel oncology drug targets and is uniquely poised to discover first-in-class ADC targets. What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans?

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Drug Target Review

APRIL 9, 2024

In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects.

RNA 64

RNA Cell Biology Clinical Development DNA 64

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

PLOS: DNA Science

MARCH 28, 2024

A new drug has entered the arsenal against Duchenne muscular dystrophy (DMD), a genetic disease that affects boys and is challenging to treat. FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. Muscle makes up about 40 percent of body weight. million DNA bases.

FDA Approval 75

FDA Approval Treatment FDA DNA 75

Drug Discovery World

JANUARY 30, 2023

Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic. The latest episode of the DDW Highlights podcast is now available to listen to below.

Therapies 130

Therapies Drugs Drug Development RNA 130

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Silverback Therapeutics

RNA 52

RNA Protein Expression Therapies Disease 52

Drug Discovery World

JANUARY 2, 2024

She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer. She said: “I think that type of technology will continue to evolve and will become cheaper and cheaper.

Research 148

Research Vaccine Science Trials 148

Drug Discovery World

APRIL 25, 2023

The new life science companies BII has accepted into theVentureLabacceleration program are: AIDA Oncology which works to select the best cancer drug for each patient, using the RNA expression pattern of their tumour and machine learning.

Science 130

Science Small Molecule Disease Government 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. About Dynavax.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Dark Matter Blog

APRIL 8, 2020

Most people, and in particular most investors we spoke to in those early days, thought we were nuts – that RNA lacked the structural and molecular complexity that medicinal chemistry exploits with such great effect for proteins. One is that molecular recognition is purely a matter of physics and RNA has to play by the same rules.

RNA 52

RNA Small Molecule Synthetic Chemistry Science 52

The Pharma Data

DECEMBER 13, 2020

Their extensive experience and proven track record in advancing innovative therapies, in addition to strong leadership skills, will help us to strengthen our portfolio and accelerate technology translation to help patients in need.”.

Medical Schools 40

Medical Schools Clinical Development Hospitals RNA 40

The Pharma Data

AUGUST 30, 2021

Global Head of Cardiovascular, Renal and Metabolic Drug Development, Novartis. “As As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Food and Drug Administration (FDA) and other health authorities.

RNA 52

RNA Disease Trials Therapies 52